246 related articles for article (PubMed ID: 28507282)
1. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
[TBL] [Abstract][Full Text] [Related]
2. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors.
Goss KL; Koppenhafer SL; Waters T; Terry WW; Wen KK; Wu M; Ostergaard J; Gordon PM; Gordon DJ
Oncogene; 2021 Jan; 40(3):564-577. PubMed ID: 33191406
[TBL] [Abstract][Full Text] [Related]
3. A Single Conserved Residue Mediates Binding of the Ribonucleotide Reductase Catalytic Subunit RRM1 to RRM2 and Is Essential for Mouse Development.
Specks J; Lecona E; Lopez-Contreras AJ; Fernandez-Capetillo O
Mol Cell Biol; 2015 Sep; 35(17):2910-7. PubMed ID: 26077802
[TBL] [Abstract][Full Text] [Related]
4. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
Zhou B; Liu X; Mo X; Xue L; Darwish D; Qiu W; Shih J; Hwu EB; Luh F; Yen Y
Cancer Res; 2003 Oct; 63(20):6583-94. PubMed ID: 14583450
[TBL] [Abstract][Full Text] [Related]
5. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
6. Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication.
Foskolou IP; Jorgensen C; Leszczynska KB; Olcina MM; Tarhonskaya H; Haisma B; D'Angiolella V; Myers WK; Domene C; Flashman E; Hammond EM
Mol Cell; 2017 Apr; 66(2):206-220.e9. PubMed ID: 28416140
[TBL] [Abstract][Full Text] [Related]
7. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y
J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
[TBL] [Abstract][Full Text] [Related]
9. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
[TBL] [Abstract][Full Text] [Related]
10. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Souglakos J; Boukovinas I; Taron M; Mendez P; Mavroudis D; Tripaki M; Hatzidaki D; Koutsopoulos A; Stathopoulos E; Georgoulias V; Rosell R
Br J Cancer; 2008 May; 98(10):1710-5. PubMed ID: 18414411
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer.
Yin X; Jiang K; Zhou Z; Yu H; Yan D; He X; Yan S
Oxid Med Cell Longev; 2023; 2023():3878796. PubMed ID: 36713030
[TBL] [Abstract][Full Text] [Related]
12. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.
Rahman MA; Amin AR; Wang D; Koenig L; Nannapaneni S; Chen Z; Wang Z; Sica G; Deng X; Chen ZG; Shin DM
Clin Cancer Res; 2013 Jul; 19(13):3416-28. PubMed ID: 23719266
[TBL] [Abstract][Full Text] [Related]
13. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
[TBL] [Abstract][Full Text] [Related]
14. A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cells.
Taricani L; Shanahan F; Malinao MC; Beaumont M; Parry D
PLoS One; 2014; 9(11):e111714. PubMed ID: 25375241
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2.
Venkatesan S; Hoogstraat M; Caljouw E; Pierson T; Spoor JK; Zeneyedpour L; Dubbink HJ; Dekker LJ; van der Kaaij M; Kloezeman J; Berghauser Pont LM; Besselink NJ; Luider TM; Joore J; Martens JW; Lamfers ML; Sleijfer S; Leenstra S
Oncotarget; 2016 Sep; 7(36):58435-58444. PubMed ID: 27533080
[TBL] [Abstract][Full Text] [Related]
16. Ribonucleotide reductase M2 subunit silencing suppresses tumorigenesis in pancreatic cancer via inactivation of PI3K/AKT/mTOR pathway.
Shan J; Wang Z; Mo Q; Long J; Fan Y; Cheng L; Zhang T; Liu X; Wang X
Pancreatology; 2022 Apr; 22(3):401-413. PubMed ID: 35300916
[TBL] [Abstract][Full Text] [Related]
17. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
Jones RJ; Baladandayuthapani V; Neelapu S; Fayad LE; Romaguera JE; Wang M; Sharma R; Yang D; Orlowski RZ
Blood; 2011 Oct; 118(15):4140-9. PubMed ID: 21844567
[TBL] [Abstract][Full Text] [Related]
18. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
19. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
Sagawa M; Ohguchi H; Harada T; Samur MK; Tai YT; Munshi NC; Kizaki M; Hideshima T; Anderson KC
Clin Cancer Res; 2017 Sep; 23(17):5225-5237. PubMed ID: 28442502
[No Abstract] [Full Text] [Related]
20. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
